ENCell Co., Ltd. (KOSDAQ:456070)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cell Therapy Contract Manufacturing Organization	7.21B
Cell Therapy Contract Manufacturing Organization Growth	-31.51%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
South Korea	6.65B
South Korea Growth	-35.82%
United States	554.75M
United States Growth	253.40%

Data Source: Finnhub Last updated: Mar 31, 2026

Financial data is provided by Finnhub and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 28, 2026

Data Sources Report a data error